Linezolid Resistance in Sequential<i>Staphylococcus aureus</i>Isolates Associated with a T2500A Mutation in the 23S rRNA Gene and Loss of a Single Copy of rRNA

Meka, Venkata G.; Pillai, Satish K.; Sakoulas, George; Wennersten, Christine; Venkataraman, Lata; DeGirolami, Paola C.; Eliopoulos, George M.; Moellering, Robert C.; Gold, Howard S.

doi:10.1086/421471

Cited by 215 publications

(145 citation statements)

References 22 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…The most frequent mutation associated with linezolid resistance in both staphylococci and enterococcal clinical strains is G2576T (Escherichia coli 23S rRNA gene numbering) (8,25,29). Another mutation (T2500A) was characterized in a single patient bloodstream isolate of MRSA (17). Some additional mutations that have been found solely in vitro include the following: G2447T in S. aureus and G2505A, G2512T, G2513T, and C2610G in enterococci (20,31).…”

mentioning

confidence: 99%

Clinical and Microbiological Aspects of Linezolid Resistance Mediated by the cfr Gene Encoding a 23S rRNA Methyltransferase

et al. 2008

View full text Add to dashboard Cite

The cfr (chloramphenicol-florfenicol resistance) gene encodes a 23S rRNA methyltransferase that confers resistance to linezolid. Detection of linezolid resistance was evaluated in the first cfr-carrying human hospital isolate of linezolid and methicillin-resistant Staphylococcus aureus (designated MRSA CM-05) by dilution and diffusion methods (including Etest). The presence of cfr was investigated in isolates of staphylococci colonizing the patient's household contacts and clinical isolates recovered from patients in the same unit where MRSA CM-05 was isolated. Additionally, 68 chloramphenicol-resistant Colombian MRSA isolates recovered from hospitals between 2001 and 2004 were screened for the presence of the cfr gene. In addition to erm(B), the erm(A) gene was also detected in CM-05. The isolate belonged to sequence type 5 and carried staphylococcal chromosomal cassette mec type I. We were unable to detect the cfr gene in any of the human staphylococci screened (either clinical or colonizing isolates). Agar and broth dilution methods detected linezolid resistance in CM-05. However, the Etest and disk diffusion methods failed to detect resistance after 24 h of incubation. Oxazolidinone resistance mediated by the cfr gene is rare, and acquisition by a human isolate appears to be a recent event in Colombia. The detection of cfr-mediated linezolid resistance might be compromised by the use of the disk diffusion or Etest method.

show abstract

mentioning

confidence: 99%

Clinical and Microbiological Aspects of Linezolid Resistance Mediated by the cfr Gene Encoding a 23S rRNA Methyltransferase

et al. 2008

View full text Add to dashboard Cite

show abstract

“…45 A higher incidence of drug-related adverse events occurred with quinopristin/dalfopristin as compared to other agents. 46 For those patients receiving comparator agents, the most common reason for discontinuation was treatment failure (12%). 46 Furthermore, quinupristin/dalfopristin was compared to vancomycin in patients with hospital-acquired pneumonia.…”

Section: Quinupristin/dalfopristinmentioning

confidence: 99%

“…46 For those patients receiving comparator agents, the most common reason for discontinuation was treatment failure (12%). 46 Furthermore, quinupristin/dalfopristin was compared to vancomycin in patients with hospital-acquired pneumonia. 47 Successful outcomes were similar at 56% for quinupristin/dalfopristin and 58% for vancomycin.…”

Section: Quinupristin/dalfopristinmentioning

confidence: 99%

Novel pharmaceutical molecules against emerging resistant gram-positive cocci

Manfredi¹,

Sabbatani²

2010

Braz J Infect Dis

View full text Add to dashboard Cite

Introduction: methicillin-and also vancomycin (glycopeptide)-resistant Gram-positive organisms have emerged as an increasingly problematic cause of hospital-acquired infections, also spreading into the community. Vancomycin (glycopeptide) resistance has emerged primarily among Enterococci, but the MIC values of vancomycin for the entire Staphylococcus species are also increasing worldwide. Material and Methods: the aim of our review is to evaluate the efficacy and tolerability of newer antibiotics with activity against methicillin-resistant and glycopeptide-resistant Gram-positive cocci, on the ground of our experience at a tertiary care metropolitan Hospital, and the most recent literature evidences in this field. Results: Quinupristin-dalfopristin, linezolid, daptomycin, and tigecycline show an excellent in vitro activity, comparable to the activity of vancomycin and teicoplanin for methicillin-resistant staphylococci, and superior to the one that vancomycin for vancomycin-resistant isolates. Dalbavancin, televancin, and oritavancin are new lipoglycopeptide agents with excellent activity against Gram-positive cocci, and have superior pharmacodynamics properties compared to vancomycin. We review the bacterial spectrum, clinical indications and practical use, pharmacologic properties, and expected adverse events and contraindications associated with each of these novel antimicrobial agents, compared with the present standard of care. Discussion: linezolid activity is substantially comparable to that of vancomycin in patients with methicillin-resistant Staphylococcus aureus (MRSA) pneumonia, although its penetration into the respiratory tract is exceptionally elevated. Tigecycline has activity against both Enterococus species and MRSA; it is also active against a broad spectrum of Enterobacteriaceae and anaerobes, which allows for use intraabdominal, diabetic foot and surgical infections. Daptomycin has a rapid bactericidal activity for Staphylococcus aureus and it is approved in severe complications, such as bacteremia and right-sided endocarditis. It cannot be used to treat pneumonia and respiratory diseases, due to its inactivation in the presence of pulmonary surfactant.

show abstract

“…Considering the ever growing antibiotic resistance developed by many bacteria, there is an immense need for new compounds with new mode of actions, for treatment of bacterial infections [10]. The need for new antibiotics continues to be a still standing challenge [11]. 1,3,5-Triazacyclohexanes containing halides exhibit high biological activity since they contain CN group and halogen atom as pharmacophore.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and antimicrobial activity of 1,3-bis-butyl-5-(4-iodophenyl)-1,3,5-triazacyclohexane

et al. 2017

View full text Add to dashboard Cite

Linezolid Resistance in SequentialStaphylococcus aureusIsolates Associated with a T2500A Mutation in the 23S rRNA Gene and Loss of a Single Copy of rRNA

Cited by 215 publications

References 22 publications

Clinical and Microbiological Aspects of Linezolid Resistance Mediated by the cfr Gene Encoding a 23S rRNA Methyltransferase

Clinical and Microbiological Aspects of Linezolid Resistance Mediated by the cfr Gene Encoding a 23S rRNA Methyltransferase

Novel pharmaceutical molecules against emerging resistant gram-positive cocci

Synthesis and antimicrobial activity of 1,3-bis-butyl-5-(4-iodophenyl)-1,3,5-triazacyclohexane

Contact Info

Product

Resources

About